Icon (ICLR) Downgraded by ValuEngine to “Hold”

ValuEngine downgraded shares of Icon (NASDAQ:ICLR) from a buy rating to a hold rating in a report issued on Tuesday morning, ValuEngine reports.

Several other research firms have also recently weighed in on ICLR. Barclays increased their price objective on shares of Icon from $130.00 to $140.00 and gave the stock an equal weight rating in a research report on Thursday, February 21st. SunTrust Banks reiterated a buy rating and set a $161.00 price objective on shares of Icon in a research report on Monday, February 25th. BidaskClub cut shares of Icon from a buy rating to a hold rating in a research report on Tuesday, March 5th. Wolfe Research began coverage on shares of Icon in a research report on Tuesday, April 2nd. They set an outperform rating for the company. Finally, Zacks Investment Research upgraded shares of Icon from a sell rating to a hold rating in a research report on Tuesday, January 15th. Three investment analysts have rated the stock with a sell rating, two have issued a hold rating and nine have given a buy rating to the company’s stock. Icon has a consensus rating of Hold and an average price target of $153.40.

Shares of NASDAQ ICLR opened at $133.19 on Tuesday. Icon has a 52-week low of $116.50 and a 52-week high of $155.33. The company has a quick ratio of 2.18, a current ratio of 2.18 and a debt-to-equity ratio of 0.26. The company has a market capitalization of $7.39 billion, a price-to-earnings ratio of 22.49, a price-to-earnings-growth ratio of 1.71 and a beta of 0.65.

Icon (NASDAQ:ICLR) last posted its quarterly earnings data on Wednesday, February 20th. The medical research company reported $1.62 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.60 by $0.02. Icon had a net margin of 12.43% and a return on equity of 26.01%. The company had revenue of $679.03 million during the quarter, compared to analysts’ expectations of $675.04 million. During the same period in the prior year, the company posted $1.43 earnings per share. Icon’s revenue for the quarter was up 49.2% compared to the same quarter last year. As a group, research analysts expect that Icon will post 6.82 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of the stock. Commonwealth Equity Services LLC boosted its stake in Icon by 4.8% during the fourth quarter. Commonwealth Equity Services LLC now owns 2,197 shares of the medical research company’s stock worth $283,000 after acquiring an additional 101 shares in the last quarter. Benjamin F. Edwards & Company Inc. boosted its stake in Icon by 36.6% during the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 433 shares of the medical research company’s stock worth $56,000 after acquiring an additional 116 shares in the last quarter. CWM LLC boosted its stake in Icon by 211.8% during the fourth quarter. CWM LLC now owns 212 shares of the medical research company’s stock worth $27,000 after acquiring an additional 144 shares in the last quarter. Mackenzie Financial Corp boosted its stake in Icon by 10.0% during the fourth quarter. Mackenzie Financial Corp now owns 1,897 shares of the medical research company’s stock worth $245,000 after acquiring an additional 173 shares in the last quarter. Finally, Rehmann Capital Advisory Group boosted its stake in Icon by 75.5% during the third quarter. Rehmann Capital Advisory Group now owns 416 shares of the medical research company’s stock worth $64,000 after acquiring an additional 179 shares in the last quarter. 87.79% of the stock is currently owned by institutional investors and hedge funds.

Icon Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development services to the pharmaceutical, biotechnology, and medical device industries in Ireland, rest of Europe, the United States, and internationally. It specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Read More: Investing in Growth Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Icon (NASDAQ:ICLR)

Receive News & Ratings for Icon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Icon and related companies with MarketBeat.com's FREE daily email newsletter.